Search research articles
Contact Us
Filters
Showing results (1-10 of 61) with videos related to
Page
of 7
Sort By:
Tumori
|
January 31, 1998
[Treatment of multidrug resistance in oncology and hematology]
M Petrini, S Galimberti
Cancer Management and Research
|
December 29, 2010
Temsirolimus in the treatment of relapsed and/or refractory mantle cell lymphoma
S Galimberti, M Petrini
Journal of Chemotherapy (Florence, Italy)
|
September 10, 2003
Early reappearance of primary solid cancer in patients treated with purine analogs
R Fazzi, F Caracciolo, S Galimberti, et al.
Leukemia Research
|
November 26, 1999
An advantageous method to evaluate IgH rearrangement and its role in minimal residual disease detection
S Galimberti, F Brizzi, M Mameli, et al.
Haematologica
|
January 1, 1997
c-Jun and GST-pi expression in human plasma cells
D Di Simone, S Galimberti, L Mattii, et al.
Journal of Chemotherapy (Florence, Italy)
|
September 10, 2003
The clinical relevance of the expression of several multidrug-resistant-related genes in patients with primary acute myeloid leukemia
S Galimberti, R Testi, F Guerrini, et al.
Hematological Oncology
|
January 22, 2004
Low dose 2-CdA schedule activity in splenic marginal zone lymphomas
R Riccioni, F Caracciolo, S Galimberti, et al.
Journal of Chemotherapy (Florence, Italy)
|
August 31, 2004
Role of low-dose 2-CdA in refractory or resistant lymphoplasmocytic lymphoma
G Cervetti, S Galimberti, N Cecconi, et al.
Annals of Hematology
|
March 10, 2001
Interferon-alpha activity in a case of severe autoimmune lymphoproliferative disease
S Ceretelli, M Petrini, S Galimberti, et al.
Clinical and Experimental Rheumatology
|
January 7, 2006
High efficacy of Rituximab in indolent HCV-related lymphoproliferative disorders associated with systemic autoimmune diseases
G Cervetti, S Mechelli, R Riccioni, et al.
Page
of 7
Search research articles
Search
Showing results (1-10 of 61) with videos related to
Sort By:
Page
of 7
Tumori
|
January 31, 1998
[Treatment of multidrug resistance in oncology and hematology]
M Petrini, S Galimberti
Cancer Management and Research
|
December 29, 2010
Temsirolimus in the treatment of relapsed and/or refractory mantle cell lymphoma
S Galimberti, M Petrini
Journal of Chemotherapy (Florence, Italy)
|
September 10, 2003
Early reappearance of primary solid cancer in patients treated with purine analogs
R Fazzi, F Caracciolo, S Galimberti, et al.
Leukemia Research
|
November 26, 1999
An advantageous method to evaluate IgH rearrangement and its role in minimal residual disease detection
S Galimberti, F Brizzi, M Mameli, et al.
Haematologica
|
January 1, 1997
c-Jun and GST-pi expression in human plasma cells
D Di Simone, S Galimberti, L Mattii, et al.
Journal of Chemotherapy (Florence, Italy)
|
September 10, 2003
The clinical relevance of the expression of several multidrug-resistant-related genes in patients with primary acute myeloid leukemia
S Galimberti, R Testi, F Guerrini, et al.
Hematological Oncology
|
January 22, 2004
Low dose 2-CdA schedule activity in splenic marginal zone lymphomas
R Riccioni, F Caracciolo, S Galimberti, et al.
Journal of Chemotherapy (Florence, Italy)
|
August 31, 2004
Role of low-dose 2-CdA in refractory or resistant lymphoplasmocytic lymphoma
G Cervetti, S Galimberti, N Cecconi, et al.
Annals of Hematology
|
March 10, 2001
Interferon-alpha activity in a case of severe autoimmune lymphoproliferative disease
S Ceretelli, M Petrini, S Galimberti, et al.
Clinical and Experimental Rheumatology
|
January 7, 2006
High efficacy of Rituximab in indolent HCV-related lymphoproliferative disorders associated with systemic autoimmune diseases
G Cervetti, S Mechelli, R Riccioni, et al.
Page
of 7